RANDOMIZED COMPARISON OF INTERFERON-ALPHA WITH BUSULFAN AND HYDROXYUREA IN CHRONIC MYELOGENOUS LEUKEMIA

被引：397

作者：

HEHLMANN, R ^{[1
]}

HEIMPEL, H ^{[1
]}

HASFORD, J ^{[1
]}

KOLB, HJ ^{[1
]}

PRALLE, H ^{[1
]}

HOSSFELD, DK ^{[1
]}

QUEISSER, W ^{[1
]}

LOFFLER, H ^{[1
]}

HOCHHAUS, A ^{[1
]}

HEINZE, B ^{[1
]}

GEORGII, A ^{[1
]}

BARTRAM, CR ^{[1
]}

GRIESSHAMMER, M ^{[1
]}

BERGMANN, L ^{[1
]}

ESSERS, U ^{[1
]}

FALGE, C ^{[1
]}

QUEISSER, U ^{[1
]}

MEYER, P ^{[1
]}

SCHMITZ, N ^{[1
]}

EIMERMACHER, H ^{[1
]}

WALTHER, F ^{[1
]}

FETT, W ^{[1
]}

KLEEBERG, UR ^{[1
]}

KABISCH, A ^{[1
]}

NERL, C ^{[1
]}

ZIMMERMANN, R ^{[1
]}

MEURET, G ^{[1
]}

TICHELLI, A ^{[1
]}

KANZ, L ^{[1
]}

TIGGES, FJ ^{[1
]}

SCHMID, L ^{[1
]}

BROCKHAUS, W ^{[1
]}

TOBLER, A ^{[1
]}

REITER, A ^{[1
]}

PERKER, M ^{[1
]}

EMMERICH, B ^{[1
]}

VERPOORT, K ^{[1
]}

ZANKOVICH, R ^{[1
]}

VONWUSSOW, P ^{[1
]}

PRUMMER, O ^{[1
]}

THIELE, J ^{[1
]}

BUHR, T ^{[1
]}

CARBONELL, F ^{[1
]}

ANSARI, H ^{[1
]}

机构：

[1] UNIV HEIDELBERG, KLINIKUM MANNHEIM, MANNHEIM, GERMANY

来源：

BLOOD | 1994年 / 84卷 / 12期

关键词：

D O I：

10.1182/blood.V84.12.4064.bloodjournal84124064

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

As curative bone marrow transplantation is available only to a minority of patients with chronic myelogenous leukemia (CML), drug therapy remains of central interest. Several nonrandomized studies have suggested that interferon-alpha (IFN) may prolong survival in CML. In a randomized multicenter study the influence of IFN versus busulfan or hydroxyurea (HU) on survival of Philadelphia-positive (Ph+) CML was examined. A total of 513 Ph+ patients were randomized for treatment as follows: 133 for IFN, 186 for busulfan, and 194 for HU. IFN-treated CML patients have a significant survival advantage over busulfan-treated (P = .008), but not over HU-treated patients (P = .44). The longer survival is due to slower progression to blast crisis. Median survival of IFN-treated patients is 5.5 years [5-year survival, 59%; 95% confidence interval (CI), 48%-70%], of busulfan-treated patients, 3.8 years (5-year survival, 32%; CI, 24%-40%), and of HU-treated patients, 4.7 years (5-year survival, 44%; CI, 36%-53%). Patients who continue on IFN survive longer than those in whom IFN is discontinued before blast crisis (P = .007). Complete hematologic IFN-responders have a survival advantage over partial responders or nonresponders (P = .02). Cytogenetic IFN-responders have no significant survival advantage over nonresponders (P = .2). Patients who attain white blood cell (WBC) counts of 10 x 10(9)/L or less have a survival advantage in the IFN (P = .007) and HU (P = .05) groups. Whereas toxicity in the IFN group was considerably higher than in the busulfan or HU groups, long-lasting cytopenias necessitating discontinuation of therapy as observed with busulfan have not been seen with IFN or HU. The problems of conventional prognostic scores (Sokal's score, Score 1) that we observed in IFN-treated patients support the idea that IFN changes the natural course of CML. We conclude that, with regard to survival of CML in the chronic phase, IFN is superior to busulfan and as effective as HU. Whether and to what extent IFN is superior to HU appears to depend, at least in part, on the degree of WBC suppression by HU-therapy and on the risk profile of the patients. (C) 1994 by The American Society of Hematology.

引用

页码：4064 / 4077

页数：14

共 50 条

[21] Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy
Kuroiwa, M
Gondo, H
Ashida, K
Kamimura, T
Miyamoto, T
Niho, Y
Tsukimori, K
Nakano, H
Ohga, S
AMERICAN JOURNAL OF HEMATOLOGY, 1998, 59 (01) : 101 - 102
[22] Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: A comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha
Hasford, J
Baccarani, M
Hehlmann, R
Ansari, H
Tura, S
Zuffa, E
BLOOD, 1996, 87 (12) : 5384 - 5391
[23] SURVIVAL OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH HYDROXYUREA OR BUSULFAN
OLIN, JA
ROBINSON, WA
HESS, JR
CLINICAL RESEARCH, 1986, 34 (01): : A107 - A107
[24] Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy
Kantarjian, HM
Giles, FJ
O'Brien, SM
Talpaz, M
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1998, 12 (01) : 31 - +
[25] SURVIVAL OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH HYDROXYUREA OR BUSULFAN
OLIN, JA
ROBINSON, WA
HESS, JR
CLINICAL RESEARCH, 1986, 34 (02): : A568 - A568
[26] Sequential cladribine and interferon-alpha (IFN) in chronic myelogenous leukemia (CML).
Saven, A
Burian, C
Kosty, M
Mason, J
Douer, D
BLOOD, 1999, 94 (10) : 279B - 279B
[27] Multiple sclerosis associated with interferon-alpha therapy for chronic myelogenous leukemia
Kataoka, I
Shinagawa, K
Shiro, Y
Okamoto, S
Watanabe, R
Mori, T
Ito, D
Harada, M
AMERICAN JOURNAL OF HEMATOLOGY, 2002, 70 (02) : 149 - 153
[28] Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase or chronic myelogenous leukemia (CML Study II)
Hehlmann, R
Heimpel, H
Hossfeld, DK
Hasford, J
Kolb, HJ
Loffler, H
Pralle, H
Queisser, W
Hochhaus, A
Tichelli, A
Fett, W
Schmitz, N
Reiter, A
Griesshammer, M
Pfeifer, W
Baumler, M
Kamp, T
Tobler, A
Eimermacher, H
Kuse, R
Berger, U
Ansari, H
BONE MARROW TRANSPLANTATION, 1996, 17 : S21 - S24
[29] Prospective comparative analysis of adverse effects during the treatment of patients with chronic myelogenous leukemia in chronic phase with interferon alpha, busulfan and hydroxyurea.
Hochhaus, A
Berger, U
Ansari, H
Hasford, J
Hehlmann, R
BLOOD, 1997, 90 (10) : 3997 - 3997
[30] Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia
Wilhelm, M
Bueso-Ramos, C
O'Brien, S
Pierce, S
Keating, M
Talpaz, M
Kantarjian, HM
LEUKEMIA, 1998, 12 (01) : 65 - 70

← 1 2 3 4 5 →